From the Research
BPC-157 does not have established, FDA-approved dosing guidelines as it is not approved as a medication for muscle injury repair. While some research suggests dosages ranging from 200-500 micrograms once or twice daily for 1-4 weeks, administered via subcutaneous injection near the injury site or orally, these are experimental protocols only. The most recent and highest quality study, 1, investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats, and found that BPC 157 (10 µg/kg, 10 ng/kg) regimen given intraperitoneally or per-orally in drinking water, till the sacrifice at 7,14,28 and 42 postoperative days, documents prominent therapy effects. However, BPC-157 remains a research peptide without sufficient human clinical trials to establish safety or efficacy profiles. The compound theoretically works by accelerating angiogenesis (formation of new blood vessels), promoting growth hormone receptors in injured tissues, and modulating nitric oxide pathways to enhance healing. Some key points to consider when evaluating the use of BPC-157 for muscle injury repair include:
- Unknown risks associated with its use
- Potential contamination concerns with unregulated products
- Possible interactions with other medications
- Lack of human clinical trials to establish safety and efficacy profiles Given the current state of evidence, it is recommended that patients consult with a healthcare provider about evidence-based treatments such as physical therapy, proper nutrition, adequate rest, and approved medications for injury management. Additionally, the use of BPC-157 should be approached with caution, and patients should be aware of the potential risks and limitations associated with its use, as noted in studies such as 2, 3, 4, and 5.